Abstract

Background: Popular medicine has been used to treat some diseases including mental disorders since the ancient times. The development of this powerful tool can bring to the actual world some benefits to improve the way of taking care of mental illnesses.

Objective: To show relevant studies about biopharmaceuticals and to infer the equivalence of using biopharmaceuticals, regarding to efficacy and safety as the chemical-type drugs in the treatment for mental disorders, assessing whether there are biomolecules that might work as biopharmaceuticals to treat, cure or mitigate different mental disorders.

Methods: A systematic review from 01.01.2004 to 25.28.2014 was performed on the databases PubMed, Scopus and Science Direct. The search was performed with the descriptor "mental disorders" and with the keywords "biopharmaceuticals" and "biomolecules". The information pertinent to the study was selected, categorized and analyzed. Of the 339 articles found, 20 met the eligibility criteria.

Results: Eastern culture, followed by Amazonian region concentrated most of the species related with popular treatment of mental disorders. Several species were revealed to act upon receptors or neurotransmitters in the Central Nervous System (CNS), which, sometimes, is a similar mechanism of action of a lot of well-known synthetic drugs on the market. It was also highlighted the use of the genetic knowled-
Introduction

It is estimated that 70% to 80% of people worldwide rely chiefly on traditional, largely herbal medicine to meet their primary health care needs. It has further been observed that a number of modern pharmaceuticals have been derived from plants used by indigenous people. Many modern drugs have been derived from observations of traditional medicinal use including aspirin, atropine, ephedrine, digoxin, morphine, quinine, reserpine, and tubocurarine. Out of the 350,000 plant species identified so far, about 35,000 (some estimated up to 70,000) are used worldwide for medicinal purposes, and less than about 0.5% of these have been chemically investigated [1, 2-8].

Various plant-derived essential oils (EOs) have been used in European, Arabic, and Mediterranean countries for the treatment of different illnesses [11, 12, 13]. India and China are the countries of vast biodiversity and traditional knowledge for using natural/herbal medicines to cure many ailments in various cultures and tribes. There has been a considerable popular interest in the use of herbal products, to treat anxiety disorder/reactions [10]. One possible explanation for the efficacy of EOs for mental disorders is that EOs may have central nervous system (CNS) acting effects [11, 14].

The search for new psychotropic medications for the treatment of diseases of the nervous system and mental illnesses has benefited enormously from ethnopharmacology. In the field of psychopharma-
cology, ethnopharmacological research has uncovered a wide spectrum of CNS-active compounds ranging from sedatives to anxiolytics to analgesics to hallucinogens [15].

Depression is a serious public mental disease. It is a major cause of disability, suicide and physical disorders [16, 17]. Depressive disorder is a prevalent psychiatric disorder, which affects 21% of the world population [18, 19]. In search for new therapeutic products for the treatment of depression, medicinal plant research has contributed significantly by demonstrating pharmacological effectiveness of different herbs or their prescriptions [20, 21, 22].

Anxiety disorders are among the most common types of mental illnesses [23, 24] with a 12-month prevalence of approximately 17% and a lifetime prevalence of almost 25% in the USA [23, 25]. Despite its high prevalence, anxiety disorder is a seriously undertreated condition, and a recent mental health survey suggests that more than half of affected patients do not receive appropriate treatment [23, 26].

The most commonly used drugs in the pharmacological treatment of anxiety are serotonin reuptake inhibitors (SRIs) and benzodiazepines [23, 27]. Fragile X syndrome, the most common cause of inherited mental retardation and autism spectrum disorders, is caused by mutations of the FMR1 gene that encodes the fragile X mental retardation protein (FMRP) [28, 29-37].

Medications such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), selective reversible inhibitors of monoamine oxidase A (RIMAs), and specific serotonin–noradrenaline reuptake inhibitors (SNRIs) are clinically employed for drug therapy [18, 38]. Also, they can impose a variety of side-effects including cardiac toxicity, hypopiesia, sexual dysfunction, body weight gain, and sleep disorder [18, 39-42].

The present review intends to show relevant studies about biopharmaceuticals and to infer the equivalence of using biopharmaceuticals, regarding to efficacy and safety as the chemical-type drugs in the treatment for mental disorders, assessing whether there are biomolecules that might work as biopharmaceuticals to treat, cure or mitigate different mental disorders. Considering the side effects caused by intake of common prescribed drug it is of fundamental importance the replacement for natural based products that has less safety concerns with equivalent or better efficacy parameters.

Methods
It was performed a qualitative systematic review of articles about incidents biopharmaceuticals used as drugs to treat, cure or mitigate different mental disorders published in electronic databases previously selected. It was conducted a search in the literature through the online databases PubMed, Scopus and Science Direct, by limiting itself to articles published between January 1, 2009 to August 25, 2014.

The reason to limit the search between 2009 and 2014 was because before this period, the number of published works were little expressive and at the same time not addressed directly the use of biopharmaceuticals on mental disorders.

The following terms were used for, searching on the Databases:
1) Biopharmaceuticals (Keyword)
2) Biologics (Keyword)
3) Mental disorders (Medical Subject Headings [MeSH]).

The analysis of the article followed eligibility criteria previously determined. The survey was carried out in six phases: 1 and 3; 2 and 3 on each database (Figure 1).

On PubMed, we used the filters MeSH Terms, Title/Abstract, Publication Dates, Free Full Text, and English on the strategy 1 and 3; and MeSH Terms, Title/Abstract, Publication dates, Full text,
and English in the strategy 2 and 3 (Figure 1). On Scopus, we used the filters All, Title/Abstract/Keywords, Publication Dates, English and Document Type (Article), on the strategy 1 and 3; Abstract, Publication Dates, English and Document Type (Article), on the strategy 2 and 3 (Figure 1). On Science Direct, we used the filters Publication Dates, Journals and Full text on the strategy 1 and 3; Publication Dates, Journals, All Fields and Abstract/Title/Keywords on the strategy 2 and 3 (Figure 1).

It was adopted the following inclusion criteria: (1) written publications in English (2) studies involving the use of biopharmaceuticals on mental

Figure 1: Flow charting showing study selection for this review.

Abbreviations: MeSH, Medical Subject Headings
disorders; (3) original articles with full text accessible through the Portal de Periódicos CAPES (The Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) a virtual library connected to the Brazilian Ministry of education with content restricted to authorized users; and (5) prospective or retrospective observational studies (descriptive or analytical, except for case studies), experimental or almost experimental. The exclusion criteria were: (1) other study designs, e.g. case reports, case series, literature reviews and comments; (2) non-original studies, including editorials, reviews, forewords, short communications and letters to the editor.

Each article was read in its entirety, and the information was entered in a spreadsheet that included authors, year of publication, the study sample description, key data, and databases. To better analyze the data, the following stage involved the comparison between the articles and the division of the results obtained from the reading of each one of them in four main categories: Relevant plants worldwide [10, 15, 16, 18, 23, 44, 46, 58, 59, 60] (ten studies); Relationship of mechanisms of action of potential biopharmaceuticals and their correlated diseases [10, 11, 15, 20, 23, 44, 46, 58, 59] (nine studies), Comparison among biopharmaceuticals and other drugs well established on the market [10, 11, 23, 44, 46] (five studies), Genetic variations and gene therapy perspectives related to mental disorders [9, 28, 58, 93, 96, 100, 134] (seven studies).

Among the 20 studies, some studies were referenced in more than one category. The categorization of studies aims to a better organizational quality systematic review and it is not compulsory that each article must be referenced only in their respective category.

Discussion

Relevant plants worldwide

Ethnopharmacology has led to the discovery of botanical medicines or natural products useful in psychiatric disorders such as anxiety and depression, sleep disorders, and dementias [15]. A combination of screening approaches to evaluate a selected sample of Amazonian ethnomedicines for indications of CNS activities that may have therapeutic applications for the treatment of cognitive deficits was used by McKenna et al [15]. Additionally, Hypericum perforatum commonly known as St. Johns Wort; is the most well-known herbal product available over the counter [10]. Previous studies have shown that a number of plants from this family, including Salvia officinalis, Salvia elegans, Salvia reuterana, and Scutellaria baicalensis have shown anti-anxiety activity [10, 43]. Stachyystibetica is distributed in the tropical and subtropical regions of the world, including in Tibet, China, India, etc. In India, it is found in the cold desert regions of the Ladakh Valley and in the mountains of Himachal Pradesh [10].
## Table 1. A new perspective of biopharmaceuticals and mental disorders treatment: a systematic review. Studies and main findings.

<table>
<thead>
<tr>
<th>Authors</th>
<th>Journal</th>
<th>Sample</th>
<th>Main Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kumar et al [10] (2013)</td>
<td>Chinese Journal of Natural Medicines</td>
<td>60 rats</td>
<td>Methanolic extracts (200 and 400 mg·kg−1) of the root, stem, leaf and whole plant of Stachys tibetica Vatke and diazepam (DZ) increased the time spent and the number of entries in the open arm significantly (**P &lt; 0.01), while they decreased the time spent and the number of entries in the closed arm. These allied parameters helped to assess the anxiolytic potential of Stachys tibetica Vatke. The results strongly justify the use of this plant for the treatment of anxiety.</td>
</tr>
<tr>
<td>Yamaguchi et al [46] (2012)</td>
<td>Journal of Ethnopharmacology</td>
<td>Male Wistar/ST rats</td>
<td>These findings suggested that yokukansan has anxiolytic effects on anxiety-like behaviors induced by both innate fear and memory-dependent fear.</td>
</tr>
<tr>
<td>Gaoa et al [16] (2011)</td>
<td>Journal of Ethnopharmacology</td>
<td>56 male Sprague-Dawley rats</td>
<td>The significant difference in metabolic profiling was observed from model group compared with drug-dose group by using the Principal Component Analysis (PCA), indicating the recovery effect of XYS on Chronic Unpredictable mild Stress (CUMS) rats.</td>
</tr>
<tr>
<td>Bisong SA, Brown R, Osim EE. [60] (2010)</td>
<td>Journal of Ethnopharmacology</td>
<td>90 male CD-1 strain of mice</td>
<td>Root bark extract from Rauwolfia vomitoria produced better behavioural effects with less distortion in motor coordination when compared to chlorpromazine and so has a great potential as an alternative antipsychotic agent compared to chlorpromazine.</td>
</tr>
<tr>
<td>Kasper et al [23] (2010)</td>
<td>International Clinical Psychopharmacology</td>
<td>221 adults suffering from anxiety disorders.</td>
<td>Lavandula oil preparation silexan is both efficacious and safe for the relief of anxiety disorder not otherwise specified. It has a clinically meaningful anxiolytic effect and alleviates anxiety related to disturbed sleep.</td>
</tr>
<tr>
<td>Dai et al [20] (2010)</td>
<td>Journal of Ethnopharmacology</td>
<td>48 male Sprague-Dawley</td>
<td>In term of anti-depression effect, high dose xiaoyaosan was the most effective and amitriptyline equaled middle dose xiaoyaosan as shown by metabolomics strategy and behavior tests.</td>
</tr>
<tr>
<td>Zhou et al [18] (2010)</td>
<td>Pharmacology, biochemistry, and behavior.</td>
<td>Male Kunming mice</td>
<td>It was demonstrated that acute and sub-chronic administration of extracts of Fructus Akebiae produced antidepressant-like effects. The results suggest that the extracts of Fructus Akebiae exert antidepressant activity.</td>
</tr>
<tr>
<td>Authors</td>
<td>Journal</td>
<td>Sample</td>
<td>Main Findings</td>
</tr>
<tr>
<td>---------</td>
<td>---------</td>
<td>--------</td>
<td>---------------</td>
</tr>
<tr>
<td>Guilmatre et al [92] (2009)</td>
<td>Archives of General Psychiatry</td>
<td>28 candidate loci</td>
<td>Recurrent or overlapping Copy Number Variations (CNVs) were found in cases at 39.3% of the selected loci. The collective frequency of CNVs at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases with mental retardation compared with controls ($P &lt; .001$, $P = .01$, and $P = .001$, respectively, Fisher exact test). Individual significance ($P = .02$ without correction for multiple testing) was reached for the association between autism and a 350-kilobase deletion located at 22q11 and spanning the PRODH and DGCR6 genes.</td>
</tr>
<tr>
<td>McKenna et al [15] (2011)</td>
<td>Journal of Ethnopharmacology</td>
<td>Approximately 300 Amazonian species</td>
<td>Ninety-one samples displayed ≥60% inhibition of radioligand binding activity in receptor assays; 135 samples displayed agonist or antagonist activity (or both) in functional assays.</td>
</tr>
<tr>
<td>Teranishi et al [44] (2013)</td>
<td>Journal of Clinical Psychopharmacology.</td>
<td>90 patients with dementia</td>
<td>Mean Neuropsychiatric Inventory in Nursing Home Version total score decreased in all 3 drug groups, with no significant between-group differences. Mini-Mental State Examination and Functional Independence Measure scores did not change significantly. Drug-Induced Extra-Pyramidal Symptoms Scale scores did not change in the yokukansan and fluvoxamine groups, but increased significantly in the risperidone group. Risperidone, yokukansan, and fluvoxamine were equally effective in the treatment of BPSD in elderly patients. However, yokukansan or fluvoxamine for BPSD showed a more favorable profile in tolerability compared with risperidone.</td>
</tr>
<tr>
<td>Knorle R [59] (2012)</td>
<td>Journal of Neural Transmission</td>
<td>S.scardica extracts</td>
<td>EC50 values were in the range of 30–40 lg/ml. Inhibition of the human serotonin transporter by the methanol extract was even more effective (EC50 1.4 lg/ml). Combining Sideritis ethanol extract and fluvoxamine resulted in a leftward shift of the fluvoxamine concentration–response curve.</td>
</tr>
<tr>
<td>Umezu T [11] (2012)</td>
<td>Phytotherapy research: PTR</td>
<td>20 plant-derived essential oils (EOs)</td>
<td>Essential oils of peppermint and chamomile exhibited CNS stimulant-like effects; that is, they increased the response rate (number of shuttlings/min) of the avoidance response. Linden also increased the response rate, however, the effect was not dose-dependent. In contrast, EOs of orange, grapefruit, and cypress exhibited CNS depressant-like effects; that is, they decreased the response rate of the avoidance response. Essential oils of eucalyptus and rose decreased the avoidance rate (number of avoidance responses/number of avoidance trials) without affecting the response rate, indicating that they may exhibit some CNS acting effects. Essential oils of 12 other plants, including juniper, patchouli, geranium, jasmine, clary sage, neroli, lavender, lemon, ylang-ylang, niaouli, vetivert and frankincense had no effect on the avoidance response in mice.</td>
</tr>
<tr>
<td>Hope et al [93] (2013)</td>
<td>Schizophrenia Research</td>
<td>322 patients with schizophrenia spectrum and bipolar disorder</td>
<td>After controlling for confounders, IL-1Ra and TNF-R1 were independently associated with Global Assessment of Functioning (GAF), and significantly correlated with Positive and Negative Syndrome Scale (PANSS) negative and positive, respectively. In addition, IL-1Ra was associated with premorbid adjustment scale (PAS), and sTNF-R1 with number of hospitalizations and psychotic episodes. Von Willebrand factor (VWF) was significantly correlated with psychotic episodes, osteoprotegerin (OPG) with hospitalizations and IL-6 with history of psychosis. Linear regression analysis showed that GAF remained associated with sTNF-R1 and IL-1Ra with PANSS, after controlling for the other clinical measures.</td>
</tr>
<tr>
<td>Authors</td>
<td>Journal</td>
<td>Sample</td>
<td>Main Findings</td>
</tr>
<tr>
<td>-------------------------</td>
<td>--------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Tost et al [96] (2013)</td>
<td>Neuropsychopharmacology</td>
<td>85 healthy Caucasian adults</td>
<td>Prior imaging genetics work, are consistent with complex effects of the BDNF Val66Met polymorphism on human brain structure, and may serve to generate hypotheses about variation in white matter microstructure in mental disorders associated with this variant.</td>
</tr>
<tr>
<td>Unternaehrer et al <a href="2012">100</a></td>
<td>Nature Transl Psychiatry</td>
<td>76 adults-43 women and 33 men-aged between 61 and 67 years</td>
<td>They found different DNA methylation states in the OXTR when comparing pre-stress, post-stress and 90-min follow-up stress measurement.</td>
</tr>
<tr>
<td>Corvin AP [9] (2010)</td>
<td>Cell adhesion &amp; Migration</td>
<td>28 CAM genes</td>
<td>ASDs and psychotic disorders may involve overlapping molecular aetiology where an accumulation of small effects from many common genetic risk variants or more highly penetrant mutations induce neuronal dysconnectivity by disrupting CAM function.</td>
</tr>
<tr>
<td>Sharkar et al [1] (2013)</td>
<td>Journal of Herbs</td>
<td>111 medicinal plants belonging to 62 families</td>
<td>Assessments of reported ethnomedicinal activity indicated that these plant species can potentially lead to the discovery of novel compounds of pharmacological interest.</td>
</tr>
<tr>
<td>Camacho-Garcia et al <a href="2012">134</a></td>
<td>Neurobiology of Diseasea</td>
<td>86 cases with autism and mental retardation and 200 controls</td>
<td>They Reported the identification of four novel independent mutations that affect nearby positions in two regions of the gene/protein. These mutations cosegregate with different psychiatric disorders other than autism and mental retardation, such as psychosis and attention-deficit/hyperactivity disorder.</td>
</tr>
<tr>
<td>Sarris et al [58] (2013)</td>
<td>Journal of Clinical Psychopharmacology.</td>
<td>75 participants with GAD and no comorbid mood disorder</td>
<td>Standardized kava may be a moderately effective short-term option for the treatment of generalized anxiety disorder (GAD). Furthermore, specific GABA transporter polymorphisms appear to potentially modify anxiolytic response to kava.</td>
</tr>
</tbody>
</table>
Yokukansan was developed in 1555 by Xue Kai and is one of the traditional Japanese medicines called kampo medicines in Japan [44, 45]. In the traditional use of yokukansan, it is useful for curbing screaming attacks, sleep terrors and hypnic myoclonia, especially in children [46]. It has been approved by the Ministry of Health, Labour and Welfare of Japan as a remedy for neurosis, insomnia, and irritability in children [44, 45]. In addition, yokukansan could be useful as one of the therapeutic drugs for the treatment of anxiety disorders and various mental disorders that have comorbid anxiety [46].

Xiaoyaosan (XYS), a well-known formula for relieving depression, was originated from the book of “Taiping HuiminHejiJufang” in Song Dynasty (960-1279 AD), consisting of Radix Bupleuri, Radix Angelicae Sinensis, Radix Paeoniae Alba, Rhizoma Atractylodis Macrocephalae, Poria, Radix Glycyrrhizae, HerbaMenthae, and Rhizoma Zingiberis Recens with dose proportion of 6:6:6:6:6:3:2:2. In traditional Chinese medicine (TCM), the XYS decoction exerts various actions, including smoothing the liver, improving the circulation of Qi to relieve depression, strengthening the spleen, and nourishing blood [16].

The German Commission E, an independent body appointed by the German Federal Health Agency in 1978 to analyze and assess the information regarding herbal medicines compiled from evidence based as well as from traditional sources, has approved lavender flowers (Lavandulaeflos) for the treatment of restlessness, insomnia, and nervous disorders of the intestines [23, 47]. Psychological and psychiatric research involving lavender preparations has been focused on the drugs’ relaxing, anxiolytic and mood alleviating [23, 48-56].

Fructus Akebiae is the dry fruit of Akebiaequina-ta (THUNB.) DECNE., a well-known medicinal plant widely distributed in China. It is recorded in the Compendium of Materia Medica that Fructus Akebiae is the major ingredient in some complex prescriptions for treating mental disorders and cognitive and behavioral deficits, including insomnia and dreaminess, loss of memory, phobias, and depressive disorders etc. Previous studies reveal that the genus Akebiae contains more than thirty types of triterpenoid saponins, and most of these triterpenoid saponins comprise hederagenin [18, 57].

Kava is a South Pacific plant medicine with traditional cultural use as an inebriant and modern clinical use as an anxiolytic. Kava extracts are, however, still currently available in the United States, Australia, and the South Pacific Islands. In response to safety concerns, the World Health Organization commissioned a report assessing the risk of kava products. Recommendations from this report suggest that products from water-based suspensions should be developed and tested in clinical studies and that these formulations should preferentially be used over acetic and ethanolic extracts [58].

Within the Mediterranean area the pharmacological profile of Sideritis scardica extracts as triple monoamine reuptake inhibitors suggests their use in the phytochemical therapy of mental disorders associated with a malfunctioning monoaminergic neurotransmission, such as anxiety disorders, major depression, attention-deficit hyperactivity disorder, mental impairment or neurodegenerative diseases. The genus Sideritis (Lamiaceae) comprises about 150 species distributed mainly in the Mediterranean area and in the moderate zones of Asia [59].

One of the herbs used for the treatment of psychiatric disorders in Nigeria is Rauwolfia vomitoria Afzelius which belongs to the family Apocynaceae [60, 61]. Herbal preparations of Rauwolfia vomito-ria are used by traditional medicine practitioners in the treatment of mental disorders, as demonstrated by decreased anxiety related behaviour in the mice [60].
Relationship of mechanisms of action of potential biopharmaceuticals and their correlated diseases


The serotonin system mediates a wide variety of functions including perception, emotion, attention, and cognition [15, 70]. Serotonin receptors putatively involved in the mediation of cognitive functions include 5HT1A, 5HT2A, 5HT4, and 5HT6; not surprisingly these are promising targets for development of cognition-enhancing medications [15, 71, 72].

A disturbance in the glutamatergic system may be associated with Behavioral and Psychological Symptoms of Dementia (BPSD). Yokukansan improved glutamate uptake and inhibited glutamate-induced neuronal death in a dose-dependent manner, thereby exerting a neuroprotective effect by improvement of the dysfunction of astrocytes. It seems that protection of the neuronal cells by glutamate uptake may be involved in the mechanisms of yokukansan [44]. However, yokukansan produced anxiolytic effects mediated through 5-HT1A receptors on the learned fear [46].

The extracts of different parts of Stachystibetica had different anxiolytic effects, and the effects may be due to the presence of different classes of chemical constituents and variation in their concentration. The other reason for the effects may be due to the synergism and antagonism actions and competence towards the receptors like benzodiazepines, serotonin, GABA, dopamines, adrenergic, cholinergic, histamines, etc [10].

Lavender oil potentiated the binding of GABA on GABAA receptors in Xenopus oocytes [23, 73] and showed spasmylocytic activity in a guinea-pig ileum smooth muscle preparation [20, 74].

Numerous in vivo and in vitro models suggest several mechanisms by which kava may mediate a broad spectrum of psychopharmacologic actions from its psychoactive constituents, known as kavalactones. These actions include blockade of voltage-gated sodium ion channels, reduced excitatory neurotransmitter release from blockade of calcium ion channels, enhanced ligand binding to F-aminobutyric acid (GABA) type A receptors, reversible inhibition of monoamine oxidase B, inhibition of cyclooxygenase, and reduced neuronal reuptake of dopamine and noradrenaline [58, 75-84].

Recently, the effects of Sideritis preparations on the central nervous system have come into the focus of research. Aqueous and alcoholic extracts of S. scardica have turned out to act as triple monoamine reuptake inhibitors in vitro, inhibiting the uptake of serotonin, noradrenaline and dopamine by their respective transporters. These findings allow new perspectives on the potential use of S. scardica extracts, as the pharmaceutical industry has made considerable efforts to develop chemically defined triple monoamine reuptake inhibitors [59].

Comparison among biopharmaceuticals and other drugs well established on the market

According to Teranishiet al [44], severe adverse events were experienced by 11 patients: 5 in the risperidone group, 3 in the yokukansan group, and 3 in the fluvoxamine group. Improvements in Neuropsychiatric Inventory in Nursing Home Version (NPI-NH) score suggested that risperidone, yokukansan, and fluvoxamine were equally efficacious in treating BPSD in this elderly population. Yokukansan also reduced the NPI-NH scores. None of risperidone, yokukansan, or fluvoxamine impaired cognitive function measured by Mini-Mental State Examination (MMSE) and daily life function measured by Functional Independence Measure.
(FIM) throughout the 8-week period. Yokukansan and fluvoxamine would be generally better tolerated compared with antipsychotic drugs, such as risperidone [44].

Peppermint (MINT) and Chamomile (CHA) exhibited CNS stimulant-like effects; that is, they increased the response rate. Linden also increased the response rate. Orange (ORA), grapefruit (GRAP) and cypress (CYP) exhibited CNS depressant-like effects; that is, they decreased the response rate. The eucalyptus (EUC) and rose (ROS) oils might also act as CNS depressants because they decreased the avoidance rate. However, these two EOs are distinguishable from typical CNS depressants examined in the present study, including chlorpromazine (CPZ), haloperidol (HAL), diazepam (DZ) and physostigmine (PHYS), as EUC and ROS did not produce any effects on the response rate [11].

Kumar et al [10] have reported that All of the extracts of Stachyssbetica at a dose of 200 and 400 mg·kg\(^{-1}\) significantly increased the percentage of time spent and the arm entries in the open arms, and decreased the number of entries and duration of time spent in the closed arms. In a similar fashion, the standard drug, diazepam, increased the percentage of time spent and the percentage of arm entries in the open arms. Additionally, all of the extracts and DZ decreased the time spent at the center of the maze or the latency along with closed arm returns and the DZ and methanol extract of the whole plant of Stachyssbetica (SMW) did not show the fecal bolus while other groups had reduced fecal bolus (**P < 0.01), as compared to control, showing that the behavioral alterations induced by the extracts in the Elevated Plus Maze (EPM) are consistent with an anxiolytic effect, similar to that of diazepam [10].

The anxiolytic action of lavender is supported by several small or medium-sized clinical trials [23, 45-52]. Furthermore, were demonstrated that well-defined preparation from Lavandula angustifolia in an immediate release capsule, silexan, administered orally at a dose of 80 mg/day is both efficacious and safe for relief of anxiety disorder not otherwise specified (NOS). The drug was determined to have a meaningful anxiolytic effect and to alleviate anxiety related disturbances of sleep while improving the physical and mental well-being. Taking into account that the tolerability of the herbal extract was on one level with placebo, the absence of unwanted sedative effects and the convenient once daily administration of silexan may emerge as a gentle therapeutic alternative in the treatment of anxiety [23].

**Genetic variations and gene therapy perspectives related to mental disorders**

Recently, Guilmatre et al [92] collected information in different sources about candidates for a possible gene therapy and their pathways, elucidating which location of a gene can be responsible for each related mental disorder [92].

The underlying pathological mechanisms of severe mental disorders are still largely unknown. The disorders are highly heritable [93, 94] with complex genetic and environmental interactions involved [93, 95]. However, the specific mechanisms involved remain elusive [93].

In recent years, imaging genetics has emerged as a popular approach with which to explore the effects of genetic variation on measures of brain structure and function, but initial studies are often followed by inconsistent results. Among others, BDNF Val66Met has previously been implicated as genetic risk factor for bipolar disorder, schizophrenia and depression [96, 97-99]. Additionally, Tost et al [96] have found evidence of BDNF Val66Met genotype effects on white matter microstructure in healthy young Caucasian adults manifesting as reductions in measures of coherent spatial orientation of white matter in Val/Val homozygotes, which may serve to generate hypotheses about the changes in white matter structure in disorders that have
been associated with the Val allele, even though between-study differences in methods may contribute to the observed heterogeneity in genetic association findings [96].

Disruption of a number of these genes (including NRXN1, CNTNAP2 and CASK) are known to cause diverse neurodevelopmental brain disorder phenotypes including schizophrenia, autism, learning disability and specific language disorder. Taken together these studies bring the cell adhesion molecule (CAM) pathway sharply into focus for more comprehensive DNA sequencing to identify the critical genes, and investigate their relationships and interaction with environmental risk factors in the expression of many seemingly different neurodevelopmental disorders [9].

DNA methylation is an epigenetic mechanism related to mental and physical health and disease. Aberrant DNA methylation has been implicated in the etiology of various mental disorders including, depression, psychotic disorders, post-traumatic stress disorder, autism, eating disorders, and substance dependence but also has an important role in the pathology of physical illnesses, such as cancer. Thereby DNA methylation provides a biological basis for gene–environment interactions relevant to mental health, animal and human studies have found that early life experiences can alter DNA methylation and affect gene expression and behavior [100, 101-131].

It was found methylation stress-associated DNA changes in one of two OXTR target sequences but not in the assessed target sequence of BDNF, suggesting a considerable variation in the sensitivity of short-term DNA methylation responses among different stress-related genes. For OXTR1, we found an increase in DNA methylation from pre-stress to post-stress and a decrease from post-stress to follow-up. In OXTR2, methylation decreased from post-stress to follow-up only. Notably, in OXTR1 the time-associated changes, as well as the difference from post-stress to follow up, remained significant even after controlling for blood cell count [100].

Regarding BDNF, our results suggest that in the periphery, DNA methylation in BDNF remains stable after a short and non-recurring psychosocial stressor. Previous studies found lifelong and transgene-rational perpetuation of changes in BDNF methylation after early-life adversity [100, 131]. Fuchikami et al [132] recently suggested DNA methylation of BDNF in peripheral blood as a diagnostic biomarker of major depression [100, 132]. These results and our finding implicate that BDNF methylation has a long-term, rather than a short-term, role in stress adaptation [100].

The added novel finding of the study, concerning a possible association of specific genetic variants within the SLC6A1 locus encoding GABA transporter modify response, is intriguing; kava is known to affect anxiolytic activity from the kavalactone constituents effects on GABA pathways. Although not directly related to pharmacodynamics drug response, a study by Thoeringer et al [133] found that the frequency of the GABA transporter rs2697153 G-allele is significantly more prevalent in people with anxiety disorders, with the protective effect of those with A-alleles having an odds ratio of 2.17 (95% confidence interval, 1.46Y3.24) [58, 133]. Interestingly, our findings suggest that the number of A-alleles corresponds with the likelihood of a favorable response to kava [58].

In the last years, mutations in neurexin and neurexin genes have been associated with Autism Spectrum Disorders (ASD), such as the identification of four novel mutations of NRXN1β in a sample of 86 patients with autism and Mental Retardation that in larger populations combined with functional analysis of ASD-associated mutations will help clarify the disease mechanisms [134].

Fragile X syndrome is caused by lack of fragile X mental retardation protein (FMRP) due to silencing of the FMR1 gene. The metabotropic glutamate
receptors (mGluRs) in the central nervous system contribute to higher brain functions including learning/memory, mental disorders and persistent pain. The transcription factor cyclic AMP-responsive element binding protein (CREB) is involved in important neuronal functions, such as synaptic plasticity and neuronal survival. It was shown in previous studies that stimulation of Group I mGluR-regulated FMRP and activated CREB in anterior cingulate cortex (ACC), a key region for brain cognitive and executive functions, suggesting that activation of Group I mGluRs may upregulate FMRP through CREB signaling pathway. Therefore, was proposed that CREB is the key transcription factor in regulation of FMRP by Group I mGluRs in ACC neurons, and may help to further elucidate the molecular and cellular mechanisms underlying fragile X syndrome [28].

Conclusion
Many plants and natural entities have been used as sources of biomolecules that may be used as biopharmaceuticals to treat, cure or mitigate mental disorders. In this review, no approved biopharmaceutical was found within the last 5 years to treat mental disorders, which highlights the need of investing in this area, supported by the fact that there is a potential field where biomolecules may serve as new drugs to treat those disorders.

Several biomarkers have been related to mental disorders with regards to their level and the severity of disease, such as sTNF-R1 and IL-1Ra17. Those markers may be targets of biologics that would help to keep the level of those molecules normal. Additionally, many genes have been suggested as signatures of mental disorders, potentially opening avenues for gene therapy or therapies based on maintaining normal epigenetic profile in humans.

The popular medicine has an important role in providing natural sources that have been known as active compounds used to treat mental disorders. However, those substances have not been largely characterized and studied at a clinical level, demonstrating the field of biopharmaceuticals provides an unexplored area to be developed. Therefore, this field is significant and can revolute the future of current medicines used to treat mental disorders.

Acknowledgments
We are grateful to the Suicidology Research group - Federal University of Ceará (UFC) / National Council for Scientific and Technological Development (CNPq). We would also like to thank the Scientific Writing Lab (LABESCI) – Faculty of Medicine, Federal University of Cariri (UFCA), to the LABESCI – Biotechnology, UFC.

Conflict of interest
The authors have no conflicts of interest or financial ties to report.

References


70. Roth BL, Hanizavareh SM, Blum AE. 2004b. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berlin) 174, 17 - 24.


